RecruitingPhase 1NCT06313593

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms

Sponsor

Incyte Corporation

Enrollment

186 participants

Start Date

Aug 8, 2024

Study Type

INTERVENTIONAL

Conditions

Myeloproliferative Neoplasms

Summary

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCB160058 and a drug called Standard disease-directed therapy for people with myeloproliferative neoplasms. The study is currently recruiting participants at 30 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCB160058

Oral; Tablet

DRUGStandard disease-directed therapy

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Locations(30)

The University of Alabama At Birmingham

Birmingham, Alabama, United States

Stanford University

Palo Alto, California, United States

Moffitt Cancer Center

Tampa, Florida, United States

Northwestern University

Chicago, Illinois, United States

The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center

Fairway, Kansas, United States

University of Michigan

Ann Arbor, Michigan, United States

Cornell Medical Center

New York, New York, United States

Icahn School of Medicine At Mount Sinai

New York, New York, United States

Sloan Kettering Institute For Cancer Research

New York, New York, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Md Anderson Cancer Center

Houston, Texas, United States

Princess Margaret Cancer Center

Toronto, Ontario, Canada

Hopital Maisonneuve-Rosemont, Montreal, Qc

Montreal, Quebec, Canada

McGill University Jewish General Hospital

Montreal, Quebec, Canada

Hospital Saint Louis

Paris, France

Institut Gustave Roussy

Villejuif, France

University Medical Center Rwth Aachen

Aachen, Germany

Universitatsklinikum Essen

Essen, Germany

Universitatsklinikum Halle (Saale)

Halle, Germany

Aou Policlinico S. Orsola-Malpighi

Bologna, Italy

Azienda Ospedaliero-Universitaria Careggi (Aouc)

Florence, Italy

Fondazione Irccs Ca Granda Ospedale Maggiore

Milan, Italy

Haukeland University Hospital

Bergen, Norway

Oslo University Hospital

Oslo, Norway

Inselspital - Universitaetsspital Bern

Bern, Switzerland

Universitatsspital Zurich

Zurich, Switzerland

Guys and St Thomas Nhs Foundation Trust

London, United Kingdom

Genesiscare Oxford

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06313593

Related Trials

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT0700811826 locations

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT0744169454 locations

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT033149741 location

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0603400213 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0593635929 locations